{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:04:30Z","timestamp":1779858270205,"version":"3.53.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13193-025-02367-9","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T07:33:50Z","timestamp":1752910430000},"page":"960-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discordance in Hormone Receptor and HER2 Status Between Primary Breast Cancer and Synchronous Ipsilateral Axillary Node"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1605-3241","authenticated-orcid":false,"given":"Govindaraj","family":"Ashokan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satishkumar","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"2367_CR1","doi-asserted-by":"crossref","unstructured":"Senkus E, Kyriakides S, Penault-Llorca F et al (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO 24(suppl 6):vi7\u201323","DOI":"10.1093\/annonc\/mdt284"},{"issue":"1","key":"2367_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H","volume":"63","author":"CL Carter","year":"1989","unstructured":"Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63(1):181\u2013187","journal-title":"Cancer"},{"issue":"7","key":"2367_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00268-010-0499-z","volume":"34","author":"AK Falck","year":"2010","unstructured":"Falck AK, Ferno M, Bendahl PO, Ryden L (2010) Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg 34(7):1434\u20131441","journal-title":"World J Surg"},{"issue":"7","key":"2367_CR4","first-page":"60","volume":"23","author":"H Kinoe","year":"2018","unstructured":"Kinoe H, Yamanouchi K, Kuba S, Morita M, Sakimura C, Kanetaka K et al (2018) Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. J BUON 23(7):60\u201366","journal-title":"J BUON"},{"issue":"21","key":"2367_CR5","doi-asserted-by":"publisher","first-page":"9233","DOI":"10.7314\/APJCP.2014.15.21.9233","volume":"15","author":"JL Ba","year":"2014","unstructured":"Ba JL, Liu CG, Jin F (2014) Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. Asian Pac J Cancer Prev 15(21):9233\u20139239","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"2367_CR6","first-page":"5744","volume":"8","author":"S Zhao","year":"2015","unstructured":"Zhao S, Xu L, Liu W, Lv C, Zhang K, Gao H et al (2015) Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer. Int J Clin Exp Pathol 8(5):5744\u20135748","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"2367_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000345467","volume":"7","author":"B Ataseven","year":"2012","unstructured":"Ataseven B, Gologan D, Gunesch A, Kehl V, Hoegel B, Beer M et al (2012) HER2\/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics. Breast Care (Basel) 7(6):465\u2013470","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"2367_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/annonc\/mdp427","volume":"21","author":"SJ Aitken","year":"2010","unstructured":"Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21(6):1254\u20131261","journal-title":"Ann Oncol"},{"issue":"2","key":"2367_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-011-1610-3","volume":"132","author":"JD Jensen","year":"2012","unstructured":"Jensen JD, Knoop A, Ewertz M, Laenkholm AV (2012) ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat 132(2):511\u2013521","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2367_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-006-9300-2","volume":"101","author":"MR D\u2019Andrea","year":"2007","unstructured":"D\u2019Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F et al (2007) Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 101(3):279\u2013284","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2367_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398\u2013405","journal-title":"J Clin Oncol"},{"issue":"3","key":"2367_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T (2019) The latest research and development into the antibody-drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer therapy. Chem Pharm Bull (Tokyo) 67(3):173\u2013185","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"8","key":"2367_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V et al (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124\u20131135","journal-title":"Lancet Oncol"},{"key":"2367_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","volume":"163","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Gandini S, Nicolo E, Trillo P, Giugliano F, Zagami P et al (2022) Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 163:35\u201343","journal-title":"Eur J Cancer"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-025-02367-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-025-02367-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-025-02367-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:36:57Z","timestamp":1779856617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-025-02367-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1007\/s13193-025-02367-9","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"value":"0975-7651","type":"print"},{"value":"0976-6952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}